UCB to acquire Zogenix
/PRNewswire/ -- Regulated information – Inside information – UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced today that the companies have entered...
Source: prnewswire.com
📰 Boxed Warning News
Page 55 - Boxed Warning News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Boxed Warning. Real-time updates on events, politics, business and more.
UCB to acquire Zogenix (2)
- Transaction broadens and builds upon UCB's role as a leader in, and our continued commitment to,...
Source: europapress.es
UCB to acquire Zogenix
/PRNewswire/ -- Regulated information – Inside information – UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced today that the companies have entered...
Source: prnewswire.com
UCB to acquire Zogenix
BRUSSELS and EMERYVILLE, Calif., Jan. 19, 2022 /PRNewswire/ -- Regulated information – Inside information – UCB (Euronext: UCB) and Zogenix (NASDA...
Source: businessinsider.com
UCB to acquire Zogenix (1)
And Zogenix (NASDAQ: ZGNX) announced today that the companies have entered into a definitive agreement under...
Source: europapress.es
UCB to acquire Zogenix (3)
- Transaction broadens and builds upon UCB's role as a leader in, and our continued commitment to,...
Source: europapress.es
UCB and Zogenix: UCB to acquire Zogenix
- Transaction broadens and builds upon UCB's role as a leader in, and our continued commitment to, addressing unmet needs of people living with epilepsy, complementing existing medicines and
Source: finanznachrichten.de
Cibinqo Approved for Refractory, Moderate to Severe Atopic Dermatitis
The FDA has approved Cibinqo (abrocitinib) for the treatment of refractory, moderate to severe atopic dermatitis.
Source: empr.com
DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference
/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, and...
United States Hc Wainwright Bioconnect Jamese Brown Norman Sussman Michaelh Arenberg Exchange Commission
Source: prnewswire.com
DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference
/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, and...
United States Hc Wainwright Bioconnect Jamese Brown Norman Sussman Michaelh Arenberg Exchange Commission
Source: prnewswire.com